Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study

Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451–1467.

Ravdin, 1992, Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study, J Clin Oncol, 10, 1284, 10.1200/JCO.1992.10.8.1284

Fitzgibbons, 2000, Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999, Arch Pathol Lab Med, 124, 966, 10.5858/2000-124-0966-PFIBC

American Society of Clinical Oncology. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7 1997 by the American Society of Clinical Oncology J Clin Oncol 1998;16:793–795.

Allred, 1993, Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer?, Am J Clin Pathol, 99, 1, 10.1093/ajcp/99.1.1

McGuire, 1991, Breast cancer prognostic factors: evaluation guidelines, J Natl Cancer Inst, 83, 154, 10.1093/jnci/83.3.154

Gasparini, 1993, Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients, J Natl Cancer Inst, 85, 1206, 10.1093/jnci/85.15.1206

Hayes, 1996, Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers, J Natl Cancer Inst, 88, 1456, 10.1093/jnci/88.20.1456

NIH. Adjuvant therapy for breast cancer. NIH consensus statement 2000;17:6–7.

Alberts, 1996, Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials, Cancer, 78, 764, 10.1002/(SICI)1097-0142(19960815)78:4<764::AID-CNCR12>3.0.CO;2-T

Clahsen, 1999, The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer, Eur J Surg Oncol, 25, 356, 10.1053/ejso.1999.0657

Elledge, 2000, Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study, Int J Cancer, 89, 111, 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W

Harvey, 1999, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol, 17, 1474, 10.1200/JCO.1999.17.5.1474

Love, 2002, Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer, J Clin Oncol, 20, 2559, 10.1200/JCO.2002.08.169

Berardo, 1995, Prognostic and predictive properties of immunohistochemical progesterone receptors in breast cancer, Proc Am Soc Clin Oncol, 14, 110

Chamness, 1979, Methods for analyzing steroid receptors in human breast cancer, 149

Clark, 1984, Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer, J Clin Oncol, 2, 1102, 10.1200/JCO.1984.2.10.1102

Press, 2002, Comparison of different antibodies for detection of progesterone receptor in breast cancer, Steroids, 67, 799, 10.1016/S0039-128X(02)00039-9

Allred, 1993, Immunohistochemistry on histological sections made from small (50 mg) samples of pulverized breast cancer, J Histotechn, 16, 117, 10.1179/his.1993.16.2.117

Allred, 1993, Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer, J Natl Cancer Inst, 85, 200, 10.1093/jnci/85.3.200

Brown, 1996, Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer, Clin Cancer Res, 2, 585

Elledge, 1994, p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer, Cancer Res, 54, 3752

O'Malley, 1996, The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer, Hum Pathol, 27, 955, 10.1016/S0046-8177(96)90224-5

Ellis, 2001, Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial, J Clin Oncol, 19, 3808, 10.1200/JCO.2001.19.18.3808

Regitnig, 2002, Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories, Virchows Arch, 441, 328, 10.1007/s00428-002-0646-5

Mazumdar, 2000, Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments, Stat Med, 19, 113, 10.1002/(SICI)1097-0258(20000115)19:1<113::AID-SIM245>3.0.CO;2-O

Hilsenbeck, 1996, Practical P-value adjustment for optimally selected cutpoints, Stat Med, 15, 103, 10.1002/(SICI)1097-0258(19960115)15:1<103::AID-SIM156>3.0.CO;2-Y

Pichon, 1996, Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers, Br J Cancer, 73, 1545, 10.1038/bjc.1996.291

Therneau TM, Grambsch PM . Modeling survival data: Extending the Cox model. Springer-Verlag: New York: 2000.

Peterson, 1993, Sample size requirements and length of study for testing interaction in a 2 × k factorial design when time-to-failure is the outcome [corrected], Control Clin Trials, 14, 511, 10.1016/0197-2456(93)90031-8

Pertschuk, 1988, Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease-free survival, and clinical endocrine response, Cancer, 62, 342, 10.1002/1097-0142(19880715)62:2<342::AID-CNCR2820620219>3.0.CO;2-1

Knoop, 2001, Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients, J Clin Oncol, 19, 3376, 10.1200/JCO.2001.19.14.3376

Seymour, 1990, Estimation of PR and ER by immunocytochemistry in breast cancer. Comparison with radioligand binding methods, Am J Clin Pathol, 94, S35

Reiner, 1990, Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer, Cancer Res, 50, 7057

Pertschuk, 1990, Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival, Cancer, 66, 1663, 10.1002/1097-0142(19901015)66:8<1663::AID-CNCR2820660802>3.0.CO;2-C

Gasparini, 1992, Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer, J Cancer Res Clin Oncol, 118, 557, 10.1007/BF01225273

Hurlimann, 1993, Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas, Histopathology, 23, 239, 10.1111/j.1365-2559.1993.tb01196.x

Kommoss, 1994, Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis, Anal Quant Cytol Histol, 16, 203

Beck, 1994, Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC), Gynecol Oncol, 53, 220, 10.1006/gyno.1994.1119

Ferrer Roca, 1995, Immunohistochemical correlation of steroid receptors and disease-free interval in 206 consecutive cases of breast cancer: validation of telequantification based on global scene segmentation, Anal Cell Pathol, 9, 151

Stierer, 1995, A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer, Breast Cancer Res Treat, 36, 11, 10.1007/BF00690180

MacGrogan, 1995, Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases, Breast Cancer Res Treat, 36, 71, 10.1007/BF00690187

Layfield, 1996, Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance, J Surg Oncol, 61, 177, 10.1002/(SICI)1096-9098(199603)61:3<177::AID-JSO3>3.0.CO;2-8

Gago, 1998, Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients, J Steroid Biochem Mol Biol, 67, 431, 10.1016/S0960-0760(98)00140-X

Muller-Holzner, 1993, Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases, Breast Cancer Res Treat, 25, 47, 10.1007/BF00662400

Bardou, 2003, Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases, J Clin Oncol, 21, 1973, 10.1200/JCO.2003.09.099